Lipocine to host virtual KOL event on postpartum depression drug LPCN 1154

Lipocine will host a virtual event on June 12, 2026 featuring key opinion leaders discussing unmet needs in postpartum depression and the clinical profile of its investigational oral brexanolone LPCN 1154. The company will present Phase 3 topline results and discuss potential market positioning of the treatment candidate.